Vaccines Immunize People; Legislation Immunizes Vaccine Manufacturers. Legislation in the United States Regulating Liability for the Manufacture, Distribution and Administration of Vaccines

IF 0.1 Q4 LAW MEDICINE AND LAW Pub Date : 2021-04-23 DOI:10.18690/MLS.14.1.1-42.2021
T. Heller
{"title":"Vaccines Immunize People; Legislation Immunizes Vaccine Manufacturers. Legislation in the United States Regulating Liability for the Manufacture, Distribution and Administration of Vaccines","authors":"T. Heller","doi":"10.18690/MLS.14.1.1-42.2021","DOIUrl":null,"url":null,"abstract":"Infectious diseases have caused widespread misery, and have wreaked havoc physically, mentally, economically, politically, and socially. Fortunately, in more recent years, scientists have developed vaccines. Vaccines are generally very safe, but cause side effects in a small percentage of cases. The United States Congress has passed two major pieces of legislation that provide sweeping tort immunity to vaccine manufacturers and others. In 1986 Congress passed the National Childhood Vaccine Injury Act (NCVIA) and in 2005 it passed the Public Readiness and Emergency Preparedness Act (PREP ACT). Both Acts were passed to encourage manufacturers to develop vaccines, particularly in times of public emergencies, in exchange for expansive liability protection. Both Acts established no-fault type compensation schemes to compensate those suffering injury or death from vaccines without having to resort to typical litigation. The author discusses both Acts in detail, in the context of the current Covid-19 crisis.","PeriodicalId":54182,"journal":{"name":"MEDICINE AND LAW","volume":"31 1","pages":"1-42"},"PeriodicalIF":0.1000,"publicationDate":"2021-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"MEDICINE AND LAW","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18690/MLS.14.1.1-42.2021","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"LAW","Score":null,"Total":0}
引用次数: 0

Abstract

Infectious diseases have caused widespread misery, and have wreaked havoc physically, mentally, economically, politically, and socially. Fortunately, in more recent years, scientists have developed vaccines. Vaccines are generally very safe, but cause side effects in a small percentage of cases. The United States Congress has passed two major pieces of legislation that provide sweeping tort immunity to vaccine manufacturers and others. In 1986 Congress passed the National Childhood Vaccine Injury Act (NCVIA) and in 2005 it passed the Public Readiness and Emergency Preparedness Act (PREP ACT). Both Acts were passed to encourage manufacturers to develop vaccines, particularly in times of public emergencies, in exchange for expansive liability protection. Both Acts established no-fault type compensation schemes to compensate those suffering injury or death from vaccines without having to resort to typical litigation. The author discusses both Acts in detail, in the context of the current Covid-19 crisis.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
疫苗使人免疫;立法使疫苗制造商免疫。美国规范疫苗生产、销售和管理责任的立法
传染病造成了广泛的痛苦,并对身体、精神、经济、政治和社会造成了严重破坏。幸运的是,近年来,科学家已经研制出疫苗。疫苗通常是非常安全的,但在少数情况下会产生副作用。美国国会通过了两项主要立法,为疫苗制造商和其他机构提供全面的侵权豁免。1986年,国会通过了《国家儿童疫苗伤害法案》(NCVIA), 2005年又通过了《公共准备和应急准备法案》(PREP Act)。这两项法案的通过都是为了鼓励制造商开发疫苗,特别是在公共紧急情况下,以换取广泛的责任保护。这两项法案都确立了无过错型赔偿计划,以补偿因疫苗而受伤或死亡的人,而不必诉诸典型的诉讼。作者在当前Covid-19危机的背景下详细讨论了这两项法案。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
0.40
自引率
0.00%
发文量
0
期刊最新文献
Can a patient’s death go unpunished? Social Marketing Challenges in Western Balkans: Evidence From Kosovo Domestic Violence During the COVID-19 Pandemic – Analysis of Legal Solutions Adopted by Selected European Countries The, Of, For, In The Use of Amicable Settlement for Resolving Medical Malparctice in Indonesia The Importance of labeling products with a GMO or non-GMO label
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1